- Drug Pipelines
- April 2025
- 240 Pages
Global
From €2636EUR$3,000USD£2,274GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1757EUR$2,000USD£1,516GBP
- Report
- June 2020
- 753 Pages
Global
From €2900EUR$3,300USD£2,501GBP
- Report
- July 2024
- 73 Pages
Global
From €3500EUR$4,267USD£3,125GBP
- Report
- August 2022
- 68 Pages
Global
From €3075EUR$3,500USD£2,653GBP
- Report
- July 2025
- 50 Pages
Global
From €2328EUR$2,650USD£2,009GBP
Tamibarotene is a synthetic retinoid drug used in the treatment of acute promyelocytic leukemia (APL). It is a member of the retinoid family of drugs, which are derived from vitamin A and are used to treat a variety of cancers. Tamibarotene is used in combination with other drugs to treat APL, and is also used in combination with chemotherapy to treat other types of cancer. Tamibarotene is available in both oral and intravenous forms, and is approved for use in the United States, Europe, and other countries.
The Tamibarotene market is a rapidly growing segment of the oncology drugs market. It is used to treat a variety of cancers, including APL, and is increasingly being used in combination with other drugs to treat other types of cancer. Tamibarotene is also being studied for its potential use in other diseases, such as psoriasis and rheumatoid arthritis.
Some companies in the Tamibarotene market include AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more
